Part of California's recent awards of $11.8 million in HIV/AIDS grants includes a study measuring the effectiveness of pre-exposure prophylaxis (PrEP), The Associated Press (AP) reports. For the study, Truvada will be prescribed for 700 HIV-negative gay and bisexual men and transgender women in Los Angeles, San Diego and Long Beach who are at high risk of contracting HIV. While a 2010 study showed that PrEP involving Truvada reduced HIV risk by 44 to 73 percent, critics worry that people on PrEP might actually increase their HIV risk because they might view it an excuse not to use condoms.

To read the AP article, click here.